Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Rhea-AI Summary

Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.

Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.

Insights

Branding and Regulatory Strategist

Branding partnership advances commercial identity work for Nutriband's AVERSA™ FENTANYL; operational step, not a clinical or regulatory milestone.

Nutriband signed an agreement with Brand Institute, Inc. to develop the worldwide commercial brand name and visual identity for its lead product, the abuse‑deterrent fentanyl transdermal system currently called AVERSA™ FENTANYL. The engagement includes regulatory naming support from Drug Safety Institute, led by former agency officials, and leverages Brand Institute's stated market share of 75% of global drug name approvals and 87% of FDA approved names in 2024.

The business mechanism is straightforward: secure a proprietary, distinguishable commercial name and identity to reduce look‑alike/sound‑alike medication errors and support downstream labeling and marketing steps. This activity does not itself change clinical, regulatory approval, or commercial viability facts; it is preparatory work focused on brand differentiation and regulatory name clearance.

Dependencies and risks are explicit and operational: successful regulatory clearance of the proposed proprietary name and visual identity, and subsequent clinical and regulatory approvals for the product itself. Watch for concrete regulatory filings and name submissions timelines, any FDA/USAN/EMA feedback from Drug Safety Institute, and announcements tied to clinical or marketing milestones over the next 12–24 months.

Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.

Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.

ORLANDO, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development services to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology and has the development name AVERSA™ FENTANYL.

AVERSA™ FENTANYL has the potential to be the world’s first abuse-deterrent opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of opioids such as fentanyl.

Developing a proprietary brand name for a prescription drug product is a critical element in drug product development because the end users (doctors, pharmacists, patients) must be able to easily distinguish a proprietary name from other drug names that are phonetically similar (sound-alike names) or similar in their spelling or appearance (look-alike names). In addition, if the drug name is otherwise confusing or misleading, the patient might receive the wrong product and the subsequent medication error could lead to significant harm to the patient.

Brand Institute has been leading the market for over 20 years with a 75% share of drug name approvals globally, including 87% of FDA approved names in 2024. BI has been responsible for many of the opioid chronic pain product brand names approved by FDA, and a majority of the abuse deterrent opioid product brand names approved in the United States.

Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, will provide regulatory services, solutions and support on the project. DSI is led by former officials from US Food & Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name Council (USAN), and World Health Organization (WHO) who co-authored the naming guidance documents while with their former respective agencies.

Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband, Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

About Brand Institute, Inc., and wholly owned regulatory subsidiary, Drug Safety Institute

Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 5,000 marketed healthcare brand names and 1,800 USAN/INN nonproprietary names for nearly 1,600 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers. Drug Safety Institute is composed of former naming regulatory officials from global government health agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their former respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications to ensure safety and prevent medication errors. To learn more about Brand Institute's capabilities and experience, please visit www.brandinstitute.com and contact your local Brand Institute representative.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

FAQ

What did Nutriband announce about AVERSA FENTANYL on October 10, 2025?

Nutriband announced a partnership with Brand Institute to develop the worldwide commercial brand name and visual identity for AVERSA™ FENTANYL.

Which Nutriband subsidiary signed the naming agreement for NTRB's fentanyl patch?

The agreement was signed by Nutriband's subsidiary 4P Therapeutics.

What role will Drug Safety Institute play in the NTRB naming project?

Drug Safety Institute will provide regulatory services and naming guidance support for the brand name development.

What is AVERSA technology mentioned in the Nutriband announcement?

AVERSA is Nutriband's abuse-deterrent transdermal technology designed to incorporate aversive agents to deter abuse, diversion, misuse, and accidental exposure.

Does the press release state where Nutriband's AVERSA patents are issued?

Yes; the release states patents have been issued in 46 countries, including the United States, Europe, Japan, Korea, China, Canada, Mexico, and Australia.

How does Brand Institute position itself in pharmaceutical naming according to the announcement?

The announcement says Brand Institute has led the market for over 20 years and held a 75% share of drug name approvals globally, including 87% of FDA approved names in 2024.